- Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
- Kymera Therapeutics to Participate in Upcoming May Investor Conferences
- Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
- Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
- Kymera Therapeutics to Participate in Upcoming March Investor Conferences
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
More ▼
Key statistics
On Friday, Kymera Therapeutics Inc (KYMR:NMQ) closed at 35.60, -21.43% below its 52-week high of 45.31, set on Feb 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 35.69 |
---|---|
High | 35.69 |
Low | 34.52 |
Bid | 31.98 |
Offer | 40.00 |
Previous close | 35.60 |
Average volume | 511.19k |
---|---|
Shares outstanding | 61.36m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 2.14bn USD |
EPS (TTM) | -2.50 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼